Kaiser Permanente cancer survival rates higher
Kaiser Permanente had better 5-year survival rates among breast, colorectal, and lung cancer patients compared to the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) estimates, according to research published in September 2023 in The Permanente Journal.
Researchers in all 8 Kaiser Permanente regions worked together on this study. They compared the occurrence of cancer based on age, as well as the survival rate, for patients diagnosed with cancer at Kaiser Permanente to national statistics of occurrence and survival produced by the NCI’s SEER Program. SEER is a coordinated system of cancer registries across the United States that collects data on every case of cancer reported in 19 geographic areas, covering about 35% of the U.S. population.
“Our research found that breast cancer incidence rates—meaning discovery of new cases of cancer—were consistently higher for Kaiser Permanente than for SEER, and that colorectal and lung cancer incidence rates were lower. In addition, survival rates from these 3 cancers — breast, colorectal, and lung — were consistently higher than national estimates,” said the study’s co-lead author Erin E. Hahn, PhD, of the Kaiser Permanente Southern California Department of Research & Evaluation. “We believe that Kaiser Permanente’s focus on cancer prevention and cancer screening, use of cancer treatment pathways based on national guidelines, and use of a consistent electronic health record system that enables guideline-based care, protocols, and coordination of care across the cancer care continuum may have played a role in higher survival rates.”
Kaiser Permanente is an integrated health care organization with 12.7 million members. Researchers included all patients enrolled in all 8 Kaiser Permanente regions (Southern California, Northern California, Northwest — which includes portions of Oregon and Washington — Washington, Hawaii, Colorado, Georgia, and Mid-Atlantic States — which includes Maryland, Virginia, and Washington, D.C.). Then researchers followed the Kaiser Permanente patients diagnosed from 1999 to 2013 to determine 5-year survival rates.
Researchers compared both the rate of cancer incidence and the rate of survival.
- Kaiser Permanente survival rates were consistently higher than for SEER.
- Incidence rates for all-stage and localized-stage breast cancer were consistently higher for Kaiser Permanente than for SEER, while colorectal and lung cancer rates were lower. Researchers believe that higher incidence rates for localized breast cancer may be due to high screening rates.
- Researchers also parsed out the race and ethnicity of cancer patients at Kaiser Permanente. That analysis did not reveal disparities in the delivery of cancer screening and treatment for breast, colorectal, and lung cancer within Kaiser Permanente.
Researchers said that fluctuations in cancer occurrence and survival may reflect patterns in behaviors associated with cancer risk, such as the decline in smoking, increases in cancer screening, and availability of new treatments. For example, a 2008 spike in colorectal cancer incidence at Kaiser Permanente corresponded to the enterprisewide distribution of at-home colorectal cancer screening tests from 2006 to 2008. That, in turn, may well have led to earlier detection and subsequent improvements in survival seen among Kaiser Permanente members in 2011.
Co-lead author Debra P. Ritzwoller, PhD, of the Kaiser Permanente Colorado Institute for Health Research, said Kaiser Permanente members’ access to preventive care such as smoking cessation programs and cancer screening programs could have affected the findings of the study.
“We believe that this study shows that Kaiser Permanente’s dedication to screening and preventive care, as well as adoption of new treatments, has benefited our members,” she said.
Hahn and Ritzwoller added, though, that the findings should be interpreted cautiously given the differences in patients between Kaiser Permanente and the NCI’s SEER database. The Kaiser Permanente population is an insured, younger, and more racially diverse population than SEER’s aggregated location-specific populations.
In addition to Dr. Hahn and Dr. Ritzwoller, authors on the research include Corrine E. Muñoz-Plaza, MPH, Kaiser Permanente Southern California Department of Research & Evaluation; Jennifer Gander, PhD, Kaiser Permanente Georgia Center for Research and Evaluation; Lawrence H. Kushi, ScD, Kaiser Permanente Northern California Division of Research; Carmit McMullen, PhD, and Jenny Staab, PhD, (senior author), Kaiser Permanente Northwest Center for Health Research; Caryn Oshiro, PhD, Kaiser Permanente Hawaii Center for Integrated Health Care Research; Douglas W. Roblin, PhD, Kaiser Permanente Mid-Atlantic States Mid-Atlantic Permanente Research Institute; and Karen J. Wernli, PhD, Kaiser Permanente Washington Health Research Institute. Additionally, Dr. Hahn is associated with the Kaiser Permanente Bernard J. Tyson School of Medicine.